Prakash Aditya
Cancer immunotherapy refers to a variety of current and prospective treatment techniques for eradicating tumours by triggering antitumor immunity in the patient. Immune checkpoint blockade (ICB) therapies and chimeric antigen receptor (CAR)-engineered T-cell immunotherapies have been approved by the FDA, however they are not effective in all cancer patients. Cancer vaccines have not yet had the same clinical impact as other vaccines, but they have preventive and therapeutic potential, and they may give lifelong immunity against cancer recurrence, making them a possible component of future combinatorial immunotherapies.